Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

|Videos|February 16, 2022

Coming Soon: Real-World Evidence in the Evolving Treatment Landscape of Multiple Myeloma

Author(s)Ryan Haumschild, PharmD, MS, MBA

Episodes in this series

multiple myeloma

EP. 1 Coming Soon: Real-World Evidence in the Evolving Treatment Landscape of Multiple Myeloma

EP. 2 A Multiple Myeloma Overview

EP. 2 A Multiple Myeloma Overview

EP. 3 MM and Regimens for First- and Second-Line Treatment

EP. 3 MM and Regimens for First- and Second-Line Treatment

EP. 4 MM From the Payers’ Perspective

EP. 4 MM From the Payers’ Perspective

EP. 5 MM Healthcare Resource Utilization

EP. 5 MM Healthcare Resource Utilization

EP. 6 Decision Support Tools for MM

EP. 6 Decision Support Tools for MM

EP. 7 MM and the Limitations of RCT Data

EP. 7 MM and the Limitations of RCT Data

EP. 8 MM and Real-World Evidence

EP. 8 MM and Real-World Evidence

EP. 9 The Value of RWE in MM

EP. 9 The Value of RWE in MM

EP. 10 Incorporating RWE in MM Decision-Making

EP. 10 Incorporating RWE in MM Decision-Making

EP. 11 RWE Decision-Making Barriers

EP. 11 RWE Decision-Making Barriers

EP. 12 MM and Non-Comparative RWE

EP. 12 MM and Non-Comparative RWE

EP. 13 Educating on RWE

EP. 13 Educating on RWE

EP. 14 MM Unmet Needs

EP. 14 MM Unmet Needs

EP. 15 Incorporating RWE Into Future Decision-Making

EP. 15 Incorporating RWE Into Future Decision-Making

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Dr Irina Murakhovskaya | Image Credit: Montefiore Einstein

ENERGY Trial Shows Early Fatigue Benefit With Nipocalimab in wAIHA: Irina Murakhovskaya, MD

ByBrooke McCormick,Irina Murakhovskaya, MD

June 26th 2026

CRC animation | Image Credit: Thipphaphone - stock.adobe.com

Early-Life, Parental Factors May Help Explain Rising Early-Onset CRC Rates

ByBrooke McCormick

June 26th 2026

This segment explores how emerging data on oral selective estrogen receptor degraders are being applied in clinical practice for hormone receptor–positive, HER2-negative metastatic breast cancer.

HR-Positive Breast Cancer: Clinical Use of Oral SERDs in Combination vs Monotherapy

ByAdam Brufsky, MD, PhD,Hope Rugo, MD,Dr. Mabel Mardones, MD,Ms. Lori Brisbin, MS, MLS Healthcare Law,Dr. Lisa Raff, PharmD

Published: June 26th 2026 | Updated: June 26th 2026

This segment introduces the evolving treatment landscape in hormone receptor–positive, HER2-negative metastatic breast cancer, with a focus on the growing clinical relevance of ESR1 mutations.

HR-Positive Breast Cancer: Evolving Role of ESR1 Mutations in Endocrine Resistance

ByAdam Brufsky, MD, PhD,Hope Rugo, MD,Dr. Mabel Mardones, MD,Ms. Lori Brisbin, MS, MLS Healthcare Law,Dr. Lisa Raff, PharmD

Published: June 26th 2026 | Updated: June 26th 2026

Stamp that says "FDA Approved" in blue ink. | Image Credit: Surendra - stock.adobe.com

FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer

ByElla Hohmann, MS

June 25th 2026

Trending on AJMC

FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

More Potent and Tolerable, Azenosertib Advances as the Leading WEE1 Inhibitor

Clinicians Confront Fragmented Care and the Silent Burden of Undertreated Atopic Dermatitis

Health Care Spending to Hit $9 Trillion by 2034, According to New Analysis